In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I

Translation of the synergy between the Siremadlin (MDM2 inhibitor) and Trametinib (MEK inhibitor) combination observed in vitro into in vivo synergistic efficacy in melanoma requires estimation of the interaction between these molecules at the pharmacokinetic (PK) and pharmacodynamic (PD) levels. Th...

Full description

Bibliographic Details
Main Authors: Jakub Witkowski, Sebastian Polak, Zbigniew Rogulski, Dariusz Pawelec
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:International Journal of Molecular Sciences
Subjects:
anticancer drugs
preclinical study
pharmacokinetics
pharmacodynamics
drug combination
PBPK/PD modelling
Online Access:https://www.mdpi.com/1422-0067/23/21/12984

Internet

https://www.mdpi.com/1422-0067/23/21/12984

Similar Items